NSERumour Verification - Regulation 30(11)2 Nov 2026 · 2 Nov 2026, 08:58 pm

Rumour Verification - Regulation 30(11)

Sun Pharmaceutical Industries Limited · SUNPHARMA

✦ AI SummaryRegulatory

Sun Pharmaceutical Industries Limited clarifies news report regarding quality lapses at Assam facility, stating the matter occurred in August 2026 and does not warrant disclosure under Regulation 30 of SEBI Listing Regulations.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Clarification regarding news report relating to the Company s Assam facility

Attachments (1)

📄

SUNSEC_02112026205719_Reply_to_SEs_-_Rumour_Verification02112026.pdf

pdf

Download →
View document text
Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 02 November 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 BSE Code: 524715 NSE Code: SUNPHARMA Subject: Clarification regarding news report relating to the Company’s Assam facility Dear Sir/Madam, This is with reference to the communications received from the Stock Exchanges seeking clarification on the news report dated 30 October 2026 captioned “India orders Sun Pharma to halt eye-care drug production at plant after quality lapses” (“News Report”) and the movement in the price of the Company’s shares. In this regard, Sun Pharmaceutical Industries Limited (“Company”) submits as follows: The News Report relates to developments that occurred in August 2026 and does not concern any new event or development occurring on 30 October 2026. The matter was assessed at the relevant time and was not considered to warrant a disclosure under Regulation 30 of the SEBI Listing Regulations. As regards the share price movement, it may also be noted that the Company announced its financial results for the quarter and half year ended 30 September 2026 on 30 October 2026. The Company is not in a position to attribute the movement in its share price to the News Report or to any particular factor. The Company further confirms that it is not aware of any material event or information requiring disclosure under Regulation 30 that has not been disclosed to the Stock Exchanges and that could explain the aforesaid movement in the price of its shares. Thank you. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives.